Literature DB >> 28404847

Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Normand Blais1, Martin Gagné2, Yoshitomo Hamuro3, Patrick Rheault2, Martine Boyer2, Ann-Muriel Steff2, Guy Baudoux4, Vincent Dewar4, Josée Demers2, Jean-Louis Ruelle4, Denis Martin2.   

Abstract

The human respiratory syncytial virus (hRSV) fusion (F) protein is considered a major target of the neutralizing antibody response to hRSV. This glycoprotein undergoes a major structural shift from the prefusion (pre-F) to the postfusion (post-F) state at the time of virus-host cell membrane fusion. Recent evidences suggest that the pre-F state is a superior target for neutralizing antibodies compared to the post-F state. Therefore, for vaccine purposes, we have designed and characterized a recombinant hRSV F protein, called Pre-F-GCN4t, stabilized in a pre-F conformation. To show that Pre-F-GCN4t does not switch to a post-F conformation, it was compared with a recombinant post-F molecule, called Post-F-XC. Pre-F-GCN4t was glycosylated and trimeric and displayed a conformational stability different from that of Post-F-XC, as shown by chemical denaturation. Electron microscopy analysis suggested that Pre-F-GCN4t adopts a lollipop-like structure. In contrast, Post-F-XC had a typical elongated conical shape. Hydrogen/deuterium exchange mass spectrometry demonstrated that the two molecules had common rigid folding core and dynamic regions and provided structural insight for their biophysical and biochemical properties and reactivity. Pre-F-GCN4t was shown to deplete hRSV-neutralizing antibodies from human serum more efficiently than Post-F-XC. Importantly, Pre-F-GCN4t was also shown to bind D25, a highly potent monoclonal antibody specific for the pre-F conformation. In conclusion, this construct presents several pre-F characteristics, does not switch to the post-F conformation, and presents antigenic features required for a protective neutralizing antibody response. Therefore, Pre-F-GCN4t can be considered a promising candidate vaccine antigen.IMPORTANCE Human respiratory syncytial virus (RSV) is a global leading cause of infant mortality and adult morbidity. The development of a safe and efficacious RSV vaccine remains an important goal. The RSV class I fusion (F) glycoprotein is considered one of the most promising vaccine candidates, and recent evidences suggest that the prefusion (pre-F) state is a superior target for neutralizing antibodies. Our study presents the physicochemical characterization of Pre-F-GCN4t, a molecule designed to be stabilized in the pre-F conformation. To confirm its pre-F conformation, Pre-F-GCN4t was analyzed in parallel with Post-F-XC, a molecule in the post-F conformation. Our results show that Pre-F-GCN4t presents characteristics of a stabilized pre-F conformation and support its use as an RSV vaccine antigen. Such an antigen may represent a significant advance in the development of an RSV vaccine.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  hydrogen/deuterium exchange mass spectrometry; pre-F conformation; respiratory syncytial virus F protein; vaccine antigen

Mesh:

Substances:

Year:  2017        PMID: 28404847      PMCID: PMC5469252          DOI: 10.1128/JVI.02437-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies.

Authors:  L J Calder; L González-Reyes; B García-Barreno; S A Wharton; J J Skehel; D C Wiley; J A Melero
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

2.  Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  S R Arnold; E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  Pediatr Infect Dis J       Date:  1999-10       Impact factor: 2.129

3.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

4.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

5.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

6.  Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.

Authors:  Pedro A Piedra; Alan M Jewell; Stanley G Cron; Robert L Atmar; W Paul Glezen
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

7.  Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Authors:  Joshua J Shinoff; Katherine L O'Brien; Bhagvanji Thumar; Jana B Shaw; Raymond Reid; Wei Hua; Mathuram Santosham; Ruth A Karron
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

8.  Specificity of immobilized porcine pepsin in H/D exchange compatible conditions.

Authors:  Yoshitomo Hamuro; Stephen J Coales; Kathleen S Molnar; Steven J Tuske; Jeffrey A Morrow
Journal:  Rapid Commun Mass Spectrom       Date:  2008-04       Impact factor: 2.419

9.  Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.

Authors:  Ann R Falsey; Janet E McElhaney; Jiri Beran; Gerrit A van Essen; Xavier Duval; Meral Esen; Florence Galtier; Pierre Gervais; Shinn-Jang Hwang; Peter Kremsner; Odile Launay; Geert Leroux-Roels; Shelly A McNeil; Andrzej Nowakowski; Jan Hendrik Richardus; Guillermo Ruiz-Palacios; Suzanne St Rose; Jeanne-Marie Devaster; Lidia Oostvogels; Serge Durviaux; Sylvia Taylor
Journal:  J Infect Dis       Date:  2014-01-29       Impact factor: 5.226

10.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Authors:  Anders Krarup; Daphné Truan; Polina Furmanova-Hollenstein; Lies Bogaert; Pascale Bouchier; Ilona J M Bisschop; Myra N Widjojoatmodjo; Roland Zahn; Hanneke Schuitemaker; Jason S McLellan; Johannes P M Langedijk
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

View more
  13 in total

1.  Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.

Authors:  Jorge C G Blanco; Lurds R Fernando; Wei Zhang; Arash Kamali; Marina S Boukhvalova; Lori McGinnes-Cullen; Trudy G Morrison
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

Review 2.  Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems.

Authors:  Ellie I James; Taylor A Murphree; Clint Vorauer; John R Engen; Miklos Guttman
Journal:  Chem Rev       Date:  2021-09-07       Impact factor: 72.087

3.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

Review 4.  A multifaceted approach to RSV vaccination.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel
Journal:  Hum Vaccin Immunother       Date:  2018-06-19       Impact factor: 3.452

Review 5.  The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.

Authors:  Jing Shan; Philip N Britton; Catherine L King; Robert Booy
Journal:  Influenza Other Respir Viruses       Date:  2021-03-25       Impact factor: 4.380

6.  Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

Authors:  Jiri Beran; Jason D Lickliter; Tino F Schwarz; Casey Johnson; Laurence Chu; Joseph B Domachowske; Pierre Van Damme; Kanchanamala Withanage; Laurence A Fissette; Marie-Pierre David; Koen Maleux; Alexander C Schmidt; Marta Picciolato; Ilse Dieussaert
Journal:  J Infect Dis       Date:  2018-04-23       Impact factor: 5.226

7.  Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.

Authors:  Tino F Schwarz; Roderick A McPhee; Odile Launay; Geert Leroux-Roels; Jaak Talli; Marta Picciolato; Feng Gao; Rongman Cai; Thi Lien-Anh Nguyen; Ilse Dieussaert; Jacqueline M Miller; Alexander C Schmidt
Journal:  J Infect Dis       Date:  2019-10-22       Impact factor: 5.226

8.  Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.

Authors:  Ann-Muriel Steff; James Monroe; Kristian Friedrich; Sumana Chandramouli; Thi Lien-Anh Nguyen; Sai Tian; Sarah Vandepaer; Jean-François Toussaint; Andrea Carfi
Journal:  Nat Commun       Date:  2017-10-20       Impact factor: 14.919

9.  Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants.

Authors:  Ann-Muriel Steff; Chanel Cadieux-Dion; Gaël de Lannoy; Maria Key Prato; Xavier Czeszak; Bruno André; Dominique C Ingels; Marc Louckx; Walthère Dewé; Marta Picciolato; Koen Maleux; Laurence Fissette; Ilse Dieussaert
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

10.  Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring.

Authors:  Lori M Cullen; Marina S Boukhvalova; Jorge C G Blanco; Trudy G Morrison
Journal:  Vaccines (Basel)       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.